KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive Subjects (ASSERT)

This study has been completed.
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00549198
First received: October 24, 2007
Last updated: April 7, 2011
Last verified: April 2011
Results First Received: September 23, 2010  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Infection, Human Immunodeficiency Virus I
HIV Infection
Interventions: Drug: Abacavir/lamivudine and efavirenz
Drug: Tenofovir/Emtricitabine and efavirenz

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
ABC/3TC FDC Abacavir (ABC) 600 mg/lamivudine (3TC) 300 mg fixed dose combination (FDC) once daily (QD) plus 600 mg efavirenz QD
TDF/FTC FDC Tenofovir (TDF) 300 mg/emtricitabine (FTC) 200 mg FDC once daily (QD) plus 600 mg efavirenz QD

Participant Flow:   Overall Study
    ABC/3TC FDC     TDF/FTC FDC  
STARTED     195 [1]   197 [2]
COMPLETED     115     134  
NOT COMPLETED     80     63  
Adverse Event                 28                 26  
Insufficient Viral Load Response                 4                 2  
Protocol-defined Virological Failure                 7                 0  
Non-compliance                 2                 4  
Lost to Follow-up                 7                 8  
Treatment Eligibility Criteria Not Met                 3                 0  
Protocol Violation                 7                 2  
Investigator Decision                 4                 3  
Withdrawal by Subject                 7                 7  
Disease Progression                 1                 0  
Participant Moved                 2                 0  
Participant not able to perform Week 96                 1                 0  
Participant moved.Week 96 visit, no scan                 1                 0  
Prohibited Medication                 1                 2  
Participant planning pregnancy                 1                 0  
Participant overweight, no scan possible                 1                 0  
No scan facilities                 0                 2  
Pregnancy                 0                 3  
Not Exposed to Study Drug                 3                 4  
[1] Three participants were randomized but were not exposed to study drug (ABC/3TC).
[2] Four participants were randomized but were not exposed to study drug (TDF/FTC).



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
ABC/3TC FDC Abacavir (ABC) 600 mg/lamivudine (3TC) 300 mg fixed dose combination (FDC) once daily (QD) plus 600 mg efavirenz QD
TDF/FTC FDC Tenofovir (TDF) 300 mg/emtricitabine (FTC) 200 mg FDC once daily (QD) plus 600 mg efavirenz QD
Total Total of all reporting groups

Baseline Measures
    ABC/3TC FDC     TDF/FTC FDC     Total  
Number of Participants  
[units: participants]
  192     193     385  
Age [1]
[units: Years]
Median ( Full Range )
  38.0  
  ( 19 to 70 )  
  36.0  
  ( 18 to 66 )  
  37.0  
  ( 18 to 70 )  
Gender [1]
[units: Participants]
     
Female     33     40     73  
Male     159     153     312  
Race/Ethnicity, Customized [1]
[units: participants]
     
African American/African Heritage     26     30     56  
American Indian or Alaska Native     11     7     18  
Asian     2     5     7  
White     153     151     304  
[1] The Intent-to-Treat (ITT)-Exposed (E) Population, comprised of all randomized participants who received at least one dose of study medication, was used for all baseline characteristics.



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Mean Change From Baseline in Estimated Glomerular Filtration Rate (GFR), Calculated by Modification of Diet in Renal Disease (MDRD) Equation, at Week 48   [ Time Frame: Baseline, Week 48 ]

2.  Secondary:   Mean Change From Baseline in Estimated Glomerular Filtration Rate (GFR), Calculated by Modification of Diet in Renal Disease (MDRD) Equation, at Week 24   [ Time Frame: Baseline, Week 24 ]

3.  Secondary:   Mean Change From Baseline in Estimated Glomerular Filtration Rate (GFR), Calculated by Modification of Diet in Renal Disease (MDRD) Equation, at Week 96   [ Time Frame: Baseline, Week 96 ]

4.  Secondary:   Mean Change From Baseline in Estimated GFR, Calculated by Cockcroft-Gault Equation, at Week 24   [ Time Frame: Baseline, Week 24 ]

5.  Secondary:   Mean Change From Baseline in Estimated GFR, Calculated by Cockcroft-Gault Equation, at Week 48   [ Time Frame: Baseline, Week 48 ]

6.  Secondary:   Mean Change From Baseline in Estimated GFR, Calculated by Cockcroft-Gault Equation, at Week 96   [ Time Frame: Baseline, Week 96 ]

7.  Secondary:   Number of Participants With Decline From Baseline in Estimated GFR, Calculated by MDRD and Cockcroft-Gault Equations, of >=10 mL/Min/1.73 m^2 (mL/Min for Cockcroft-Gault), >=20 mL/Min/1.72 m^2, >=10%, and >=20% at Week 24   [ Time Frame: Baseline, Week 24 ]

8.  Secondary:   Number of Participants With Decline From Baseline in Estimated GFR, Calculated by MDRD and Cockcroft-Gault Equations, of >=10 mL/Min/1.73m^2 (mL/Min for Cockcroft-Gault), >=20 mL/Min/1.72m^2, >=10%, and >=20% at Week 48   [ Time Frame: Baseline, Week 48 ]

9.  Secondary:   Number of Participants With Decline From Baseline in Estimated GFR, Calculated by MDRD and Cockcroft-Gault Equations, of >=10 mL/Min/1.73m^2 (mL/Min for Cockcroft-Gault), >=20 mL/Min/1.72m^2, >=10%, and >=20% at Week 96   [ Time Frame: Baseline, Week 96 ]

10.  Secondary:   Number of Participants With National Kidney Foundation Chronic Kidney Disease Stage 1, 2, 3, 4, or 5 Categories of Renal Function at Week 24   [ Time Frame: Baseline, Week 24 ]

11.  Secondary:   Number of Participants With National Kidney Foundation Chronic Kidney Disease Stage 1, 2, 3, 4, or 5 Categories of Renal Function at Week 48   [ Time Frame: Baseline, Week 48 ]

12.  Secondary:   Number of Participants With National Kidney Foundation Chronic Kidney Disease Stage 1, 2, 3, 4, or 5 Categories of Renal Function at Week 96   [ Time Frame: Baseline, Week 96 ]

13.  Secondary:   Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 24   [ Time Frame: Baseline, Week 24 ]

14.  Secondary:   Percent Change From Baseline in Hip Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 24   [ Time Frame: Baseline, Week 24 ]

15.  Secondary:   Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 48   [ Time Frame: Baseline, Week 48 ]

16.  Secondary:   Percent Change From Baseline in Hip Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 48   [ Time Frame: Baseline, Week 48 ]

17.  Secondary:   Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 96   [ Time Frame: Baseline, Week 96 ]

18.  Secondary:   Percent Change From Baseline in Hip Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 96   [ Time Frame: Baseline, Week 96 ]

19.  Secondary:   Number of Participants With a Decline From Baseline in Lumbar Spine and Hip Bone Mineral Density (BMD) >=2.0% and >=6.0% at Week 24   [ Time Frame: Baseline, Week 24 ]

20.  Secondary:   Number of Participants With a Decline From Baseline in Lumbar Spine and Hip Bone Mineral Density (BMD) >=2.0% and >=6.0% at Week 48   [ Time Frame: Baseline, Week 48 ]

21.  Secondary:   Number of Participants With a Decline From Baseline in Lumbar Spine and Hip Bone Mineral Density (BMD) >=2.0% and >=6.0% at Week 96   [ Time Frame: Baseline, Week 96 ]

22.  Secondary:   Number of Participants Meeting World Health Organization (WHO) Criteria for Osteopenia (T-score of -2.5 to -1.0) and Osteoporosis (T-score of <-2.5) at Week 24   [ Time Frame: Week 24 ]

23.  Secondary:   Number of Participants Meeting World Health Organization (WHO) Criteria for Osteopenia (T-score of -2.5 to -1.0) and Osteoporosis (T-score of <-2.5) at Week 48   [ Time Frame: Week 48 ]

24.  Secondary:   Number of Participants Meeting World Health Organization (WHO) Criteria for Osteopenia (T-score of -2.5 to -1.0) and Osteoporosis (T-score of <-2.5) at Week 96   [ Time Frame: Week 96 ]

25.  Secondary:   Number of Participants Experiencing an Adverse Event (AE) Leading to Discontinuation by Week 24   [ Time Frame: Baseline to Week 24 ]

26.  Secondary:   Number of Participants Experiencing an Adverse Event (AE) Leading to Discontinuation by Week 48   [ Time Frame: Baseline to Week 48 ]

27.  Secondary:   Number of Participants Experiencing an Adverse Event (AE) Leading to Discontinuation by Week 96   [ Time Frame: Baseline to Week 96 ]

28.  Secondary:   Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Total Cholesterol at Week 24   [ Time Frame: Baseline, Week 24 ]

29.  Secondary:   Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Total Cholesterol at Week 48   [ Time Frame: Baseline, Week 48 ]

30.  Secondary:   Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Total Cholesterol at Week 96   [ Time Frame: Baseline, Week 96 ]

31.  Secondary:   Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Low-density Lipoprotein (LDL) at Week 24   [ Time Frame: Baseline, Week 24 ]

32.  Secondary:   Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Low-density Lipoprotein (LDL) at Week 48   [ Time Frame: Baseline, Week 48 ]

33.  Secondary:   Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Low-density Lipoprotein (LDL) at Week 96   [ Time Frame: Baseline, Week 96 ]

34.  Secondary:   Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting High-density Lipoprotein (HDL) at Week 24   [ Time Frame: Baseline, Week 24 ]

35.  Secondary:   Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting High-density Lipoprotein (HDL) at Week 48   [ Time Frame: Baseline, Week 48 ]

36.  Secondary:   Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting High-density Lipoprotein (HDL) at Week 96   [ Time Frame: Baseline, Week 96 ]

37.  Secondary:   Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Triglycerides at Week 24   [ Time Frame: Baseline, Week 24 ]

38.  Secondary:   Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Triglycerides at Week 48   [ Time Frame: Baseline, Week 48 ]

39.  Secondary:   Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Triglycerides at Week 96   [ Time Frame: Baseline, Week 96 ]

40.  Secondary:   Number of Participants With the Indicated Treatment-emergent Division of AIDS (DAIDS) Toxicities at Week 24   [ Time Frame: Week 24 ]

41.  Secondary:   Number of Participants With the Indicated Treatment-emergent Division of AIDS (DAIDS) Toxicities at Week 48   [ Time Frame: Week 48 ]

42.  Secondary:   Number of Participants With the Indicated Treatment-emergent Division of AIDS (DAIDS) Toxicities at Week 96   [ Time Frame: Week 96 ]

43.  Secondary:   Number of Participants With HIV-1 RNA <50 Copies/Milliliter (c/mL) and 400 c/mL at Week 24   [ Time Frame: Week 24 ]

44.  Secondary:   Number of Participants With HIV-1 RNA <50 Copies/Milliliter (c/mL) and 400 c/mL at Week 48   [ Time Frame: Week 48 ]

45.  Secondary:   Number of Participants With HIV-1 RNA <50 Copies/Milliliter (c/mL) and 400 c/mL at Week 96   [ Time Frame: Week 96 ]

46.  Secondary:   Change From Baseline in Cluster Difference 4 (CD4+) Cell Count at Week 24   [ Time Frame: Baseline, Week 24 ]

47.  Secondary:   Change From Baseline in Cluster Difference 4 (CD4+) Cell Count at Week 48   [ Time Frame: Baseline, Week 48 ]

48.  Secondary:   Change From Baseline in Cluster Difference 4 (CD4+) Cell Count at Week 96   [ Time Frame: Baseline, Week 96 ]

49.  Secondary:   Number of Participants Classified as Protocol-defined Failures With Treatment-emergent Resistance to Study Drug in the Indicated Viruses at Week 96   [ Time Frame: Week 96 ]

50.  Secondary:   Number of Participants Who Indicated "Yes" or "No" to the Question of Whether Unplanned Healthcare Resources Were Utilized   [ Time Frame: Baseline to Week 96 ]

51.  Other Pre-specified:   Exploratory Analysis of Change From Baseline in Albumin as a Ratio to Urine Creatinine at Week 96   [ Time Frame: Baseline, Week 96 ]

52.  Other Pre-specified:   Exploratory Analysis of Change From Baseline in Beta 2 Microglobulin (B2M) as a Ratio to Urine Creatinine at Week 96   [ Time Frame: Baseline, Week 96 ]

53.  Other Pre-specified:   Exploratory Analysis of Change From Baseline in N-acetyl-B-glucosaminidase (NAG) as a Ratio to Urine Creatinine at Week 96   [ Time Frame: Baseline, Week 96 ]

54.  Other Pre-specified:   Exploratory Analysis of Change From Baseline in Retinol Binding Protein (RBP) as a Ratio to Urine Creatinine at Week 96   [ Time Frame: Baseline, Week 96 ]

55.  Other Pre-specified:   Exploratory Analysis of Change From Baseline in Procollagen Type 1 Amino-terminal Propeptide (P1NP) at Week 96   [ Time Frame: Baseline, Week 96 ]

56.  Other Pre-specified:   Exploratory Analysis of Change From Baseline in Type 1 Collagen Cross-linked C-telopeptide at Week 96   [ Time Frame: Baseline, Week 96 ]

57.  Other Pre-specified:   Exploratory Analysis of Change From Baseline in Osteocalcin at Week 96   [ Time Frame: Baseline, Week 96 ]

58.  Other Pre-specified:   Exploratory Analysis of Change From Baseline in Bone Specific Alkaline Phosphatase (BSAP) at Week 96   [ Time Frame: Baseline, Week 96 ]


  Serious Adverse Events
  Hide Serious Adverse Events

Time Frame No text entered.
Additional Description Serious adverse events (SAEs) and adverse events (AEs) were collected in the Safety Population, comprised of all randomized participants who received at least one dose of study medication.

Reporting Groups
  Description
ABC/3TC FDC Abacavir (ABC) 600 mg/lamivudine (3TC) 300 mg fixed dose combination (FDC) once daily (QD) plus 600 mg efavirenz QD
TDF/FTC FDC Tenofovir (TDF) 300 mg/emtricitabine (FTC) 200 mg FDC once daily (QD) plus 600 mg efavirenz QD

Serious Adverse Events
    ABC/3TC FDC     TDF/FTC FDC  
Total, serious adverse events      
# participants affected / at risk     31/192 (16.15%)     20/193 (10.36%)  
Blood and lymphatic system disorders      
Neutropenia † 1    
# participants affected / at risk     1/192 (0.52%)     0/193 (0.00%)  
Cardiac disorders      
Acute myocardial infarction † 1    
# participants affected / at risk     0/192 (0.00%)     1/193 (0.52%)  
Congenital, familial and genetic disorders      
Porphyria non-acute † 1    
# participants affected / at risk     1/192 (0.52%)     0/193 (0.00%)  
Endocrine disorders      
Goitre † 1    
# participants affected / at risk     0/192 (0.00%)     1/193 (0.52%)  
Gastrointestinal disorders      
Abdominal hernia † 1    
# participants affected / at risk     1/192 (0.52%)     0/193 (0.00%)  
Diverticulum † 1    
# participants affected / at risk     1/192 (0.52%)     0/193 (0.00%)  
Gastritis † 1    
# participants affected / at risk     1/192 (0.52%)     0/193 (0.00%)  
Rectal haemorrhage † 1    
# participants affected / at risk     1/192 (0.52%)     0/193 (0.00%)  
General disorders      
Pyrexia † 1    
# participants affected / at risk     1/192 (0.52%)     0/193 (0.00%)  
Hepatobiliary disorders      
Cholecystitis † 1    
# participants affected / at risk     1/192 (0.52%)     0/193 (0.00%)  
Cholelithiasis † 1    
# participants affected / at risk     1/192 (0.52%)     0/193 (0.00%)  
Cholestasis † 1    
# participants affected / at risk     0/192 (0.00%)     1/193 (0.52%)  
Cytolytic hepatitis † 1    
# participants affected / at risk     0/192 (0.00%)     1/193 (0.52%)  
Hepatitis † 1    
# participants affected / at risk     0/192 (0.00%)     1/193 (0.52%)  
Immune system disorders      
Drug hypersensitivity † 1    
# participants affected / at risk     5/192 (2.60%)     1/193 (0.52%)  
Hypersensitivity † 1    
# participants affected / at risk     3/192 (1.56%)     0/193 (0.00%)  
Immune reconstitution syndrome † 1    
# participants affected / at risk     2/192 (1.04%)     0/193 (0.00%)  
Infections and infestations      
Pneumonia † 1    
# participants affected / at risk     5/192 (2.60%)     1/193 (0.52%)  
Gastroenteritis † 1    
# participants affected / at risk     2/192 (1.04%)     0/193 (0.00%)  
Lower respiratory tract infection † 1    
# participants affected / at risk     1/192 (0.52%)     1/193 (0.52%)  
Pulmonary tuberculosis † 1    
# participants affected / at risk     1/192 (0.52%)     1/193 (0.52%)  
Abscess limb † 1    
# participants affected / at risk     0/192 (0.00%)     1/193 (0.52%)  
Endocarditis † 1    
# participants affected / at risk     0/192 (0.00%)     1/193 (0.52%)  
Erysipelas † 1    
# participants affected / at risk     1/192 (0.52%)     0/193 (0.00%)  
Eye infection toxoplasmal † 1    
# participants affected / at risk     1/192 (0.52%)     0/193 (0.00%)  
Herpes Zoster † 1    
# participants affected / at risk     1/192 (0.52%)     0/193 (0.00%)  
Scrotal abscess † 1    
# participants affected / at risk     1/192 (0.52%)     0/193 (0.00%)  
Staphylococcal abscess † 1    
# participants affected / at risk     0/192 (0.00%)     1/193 (0.52%)  
Tuberculosis † 1    
# participants affected / at risk     1/192 (0.52%)     0/193 (0.00%)  
Viral infection † 1    
# participants affected / at risk     1/192 (0.52%)     0/193 (0.00%)  
Injury, poisoning and procedural complications      
Accidental overdose † 1    
# participants affected / at risk     1/192 (0.52%)     0/193 (0.00%)  
Ankle fracture † 1    
# participants affected / at risk     0/192 (0.00%)     1/193 (0.52%)  
Forearm fracture † 1    
# participants affected / at risk     0/192 (0.00%)     1/193 (0.52%)  
Humerus fracture † 1    
# participants affected / at risk     0/192 (0.00%)     1/193 (0.52%)  
Meniscus lesion † 1    
# participants affected / at risk     1/192 (0.52%)     0/193 (0.00%)  
Investigations      
Cardiac murmur † 1    
# participants affected / at risk     1/192 (0.52%)     0/193 (0.00%)  
Metabolism and nutrition disorders      
Dehydration † 1    
# participants affected / at risk     1/192 (0.52%)     0/193 (0.00%)  
Musculoskeletal and connective tissue disorders      
Back pain † 1    
# participants affected / at risk     0/192 (0.00%)     1/193 (0.52%)  
Osteoarthritis † 1    
# participants affected / at risk     0/192 (0.00%)     1/193 (0.52%)  
Neoplasms benign, malignant and unspecified (incl cysts and polyps)      
Burkitt's lymphoma † 1    
# participants affected / at risk     0/192 (0.00%)     1/193 (0.52%)  
Lymphoma † 1    
# participants affected / at risk     0/192 (0.00%)     1/193 (0.52%)  
Thymoma † 1    
# participants affected / at risk     1/192 (0.52%)     0/193 (0.00%)  
Nervous system disorders      
Convulsion † 1    
# participants affected / at risk     1/192 (0.52%)     0/193 (0.00%)  
Transient ischaemic attack † 1    
# participants affected / at risk     0/192 (0.00%)     1/193 (0.52%)  
Psychiatric disorders      
Acute stress disorder † 1    
# participants affected / at risk     0/192 (0.00%)     1/193 (0.52%)  
Apathy † 1    
# participants affected / at risk     0/192 (0.00%)     1/193 (0.52%)  
Renal and urinary disorders      
Renal failure † 1    
# participants affected / at risk     1/192 (0.52%)     0/193 (0.00%)  
Reproductive system and breast disorders      
Epididymitis † 1    
# participants affected / at risk     0/192 (0.00%)     1/193 (0.52%)  
Respiratory, thoracic and mediastinal disorders      
Asthma † 1    
# participants affected / at risk     1/192 (0.52%)     0/193 (0.00%)  
Skin and subcutaneous tissue disorders      
Rash maculo-papular † 1    
# participants affected / at risk     1/192 (0.52%)     0/193 (0.00%)  
Events were collected by systematic assessment
1 Term from vocabulary, MedDRA




  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information